###begin article-title 0
The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: Operational networks and tissue-specific growth control
###end article-title 0
###begin p 1
Present address: Dept of Physiology and Pharmacology, University of Bristol, Bristol Medical Sciences Building, University Walk, Bristol BS8 1TD, UK. Tel.: +44 0117 33 11465.
###end p 1
###begin p 2
This document may be redistributed and reused, subject to .
###end p 2
###begin title 3
Graphical abstract
###end title 3
###begin title 4
Abstract
###end title 4
###begin p 5
###xml 93 94 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 96 97 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 603 604 595 596 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 606 607 598 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 719 720 707 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 722 723 710 711 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 905 906 889 890 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 908 909 892 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 945 947 929 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 143 148 <span type="species:ncbi:9606">human</span>
Substantive evidence implicates vitamin D receptor (VDR) or its natural ligand 1alpha,25-(OH)2 D3 in modulation of tumor growth. However, both human and animal studies indicate tissue-specificity of effect. Epidemiological studies show both inverse and direct relationships between serum 25(OH)D levels and common solid cancers. VDR ablation affects carcinogen-induced tumorigenesis in a tissue-specific manner in model systems. Better understanding of the tissue-specificity of vitamin D-dependent molecular networks may provide insight into selective growth control by the seco-steroid, 1alpha,25-(OH)2 D3. This commentary considers complex factors that may influence the cell- or tissue-specificity of 1alpha,25-(OH)2 D3/VDR growth effects, including local synthesis, metabolism and transport of vitamin D and its metabolites, vitamin D receptor (VDR) expression and ligand-interactions, 1alpha,25-(OH)2 D3 genomic and non-genomic actions, Ca2+ flux, kinase activation, VDR interactions with activating and inhibitory vitamin D responsive elements (VDREs) within target gene promoters, VDR coregulator recruitment and differential effects on key downstream growth regulatory genes. We highlight some differences of VDR growth control relevant to colonic, esophageal, prostate, pancreatic and other cancers and assess the potential for development of selective prevention or treatment strategies.
###end p 5
###begin title 6
Abbreviations
###end title 6
###begin title 7
Keywords
###end title 7
###begin title 8
Keypoints
###end title 8
###begin p 9
###xml 0 1 0 1 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8226;</label>
###xml 264 265 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 267 268 263 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 316 317 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 319 320 311 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 332 334 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1 535 1 527 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="10">Complex factors influence the cell- or tissue-specificity of vitamin D biological and growth effects, including local synthesis, metabolism and transport of vitamin D and its metabolites, vitamin D receptor (VDR) expression and ligand-interactions, 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub> genomic and non-genomic actions, 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub>-mediated Ca<sup>2+</sup> flux, kinase activation, VDR interactions with specific vitamin D responsive elements within target gene promoters, VDR coregulator recruitment and differential effects on key downstream target genes.</p>
###xml 0 535 0 527 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><label>&#8226;</label><p textid="10">Complex factors influence the cell- or tissue-specificity of vitamin D biological and growth effects, including local synthesis, metabolism and transport of vitamin D and its metabolites, vitamin D receptor (VDR) expression and ligand-interactions, 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub> genomic and non-genomic actions, 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub>-mediated Ca<sup>2+</sup> flux, kinase activation, VDR interactions with specific vitamin D responsive elements within target gene promoters, VDR coregulator recruitment and differential effects on key downstream target genes.</p></list-item>
###xml 535 536 527 528 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8226;</label>
###xml 536 621 528 613 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="11">Animal and in vitro studies show cell- or tissue-restricted vitamin D growth control.</p>
###xml 535 621 527 613 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><label>&#8226;</label><p textid="11">Animal and in vitro studies show cell- or tissue-restricted vitamin D growth control.</p></list-item>
###xml 621 622 613 614 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8226;</label>
###xml 622 715 614 707 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="12">Epidemiological studies indicate vitamin D tissue-specific effects on neoplastic progression.</p>
###xml 621 715 613 707 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><label>&#8226;</label><p textid="12">Epidemiological studies indicate vitamin D tissue-specific effects on neoplastic progression.</p></list-item>
###xml 715 716 707 708 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8226;</label>
###xml 850 851 838 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 853 854 841 842 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 716 878 708 866 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="13">E-cadherin and osteopontin (OPN) are functionally antagonistic VDR target genes that orchestrate the growth response to 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub> in diverse tumor types.</p>
###xml 715 878 707 866 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><label>&#8226;</label><p textid="13">E-cadherin and osteopontin (OPN) are functionally antagonistic VDR target genes that orchestrate the growth response to 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub> in diverse tumor types.</p></list-item>
###xml 878 879 866 867 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8226;</label>
###xml 910 911 894 895 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 913 914 897 898 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 879 1137 867 1121 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="14">Consideration of 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub>-dependent signaling networks in a cell-lineage or tissue-specific context may shed light on its disparate growth regulatory effects and help exploit the promising therapeutic potential of VDR ligands, for selected cancers.</p>
###xml 878 1137 866 1121 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><label>&#8226;</label><p textid="14">Consideration of 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub>-dependent signaling networks in a cell-lineage or tissue-specific context may shed light on its disparate growth regulatory effects and help exploit the promising therapeutic potential of VDR ligands, for selected cancers.</p></list-item>
###xml 0 1137 0 1121 <list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" list-type="simple"><list-item><label>&#8226;</label><p textid="10">Complex factors influence the cell- or tissue-specificity of vitamin D biological and growth effects, including local synthesis, metabolism and transport of vitamin D and its metabolites, vitamin D receptor (VDR) expression and ligand-interactions, 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub> genomic and non-genomic actions, 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub>-mediated Ca<sup>2+</sup> flux, kinase activation, VDR interactions with specific vitamin D responsive elements within target gene promoters, VDR coregulator recruitment and differential effects on key downstream target genes.</p></list-item><list-item><label>&#8226;</label><p textid="11">Animal and in vitro studies show cell- or tissue-restricted vitamin D growth control.</p></list-item><list-item><label>&#8226;</label><p textid="12">Epidemiological studies indicate vitamin D tissue-specific effects on neoplastic progression.</p></list-item><list-item><label>&#8226;</label><p textid="13">E-cadherin and osteopontin (OPN) are functionally antagonistic VDR target genes that orchestrate the growth response to 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub> in diverse tumor types.</p></list-item><list-item><label>&#8226;</label><p textid="14">Consideration of 1&#945;,25-(OH)<sub>2</sub> D<sub>3</sub>-dependent signaling networks in a cell-lineage or tissue-specific context may shed light on its disparate growth regulatory effects and help exploit the promising therapeutic potential of VDR ligands, for selected cancers.</p></list-item></list>
*Complex factors influence the cell- or tissue-specificity of vitamin D biological and growth effects, including local synthesis, metabolism and transport of vitamin D and its metabolites, vitamin D receptor (VDR) expression and ligand-interactions, 1alpha,25-(OH)2 D3 genomic and non-genomic actions, 1alpha,25-(OH)2 D3-mediated Ca2+ flux, kinase activation, VDR interactions with specific vitamin D responsive elements within target gene promoters, VDR coregulator recruitment and differential effects on key downstream target genes.*Animal and in vitro studies show cell- or tissue-restricted vitamin D growth control.*Epidemiological studies indicate vitamin D tissue-specific effects on neoplastic progression.*E-cadherin and osteopontin (OPN) are functionally antagonistic VDR target genes that orchestrate the growth response to 1alpha,25-(OH)2 D3 in diverse tumor types.*Consideration of 1alpha,25-(OH)2 D3-dependent signaling networks in a cell-lineage or tissue-specific context may shed light on its disparate growth regulatory effects and help exploit the promising therapeutic potential of VDR ligands, for selected cancers.
###end p 9
###begin p 10
###xml 263 264 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 266 267 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 315 316 307 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 318 319 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 331 333 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Complex factors influence the cell- or tissue-specificity of vitamin D biological and growth effects, including local synthesis, metabolism and transport of vitamin D and its metabolites, vitamin D receptor (VDR) expression and ligand-interactions, 1alpha,25-(OH)2 D3 genomic and non-genomic actions, 1alpha,25-(OH)2 D3-mediated Ca2+ flux, kinase activation, VDR interactions with specific vitamin D responsive elements within target gene promoters, VDR coregulator recruitment and differential effects on key downstream target genes.
###end p 10
###begin p 11
Animal and in vitro studies show cell- or tissue-restricted vitamin D growth control.
###end p 11
###begin p 12
Epidemiological studies indicate vitamin D tissue-specific effects on neoplastic progression.
###end p 12
###begin p 13
###xml 134 135 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 137 138 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
E-cadherin and osteopontin (OPN) are functionally antagonistic VDR target genes that orchestrate the growth response to 1alpha,25-(OH)2 D3 in diverse tumor types.
###end p 13
###begin p 14
###xml 31 32 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 34 35 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
Consideration of 1alpha,25-(OH)2 D3-dependent signaling networks in a cell-lineage or tissue-specific context may shed light on its disparate growth regulatory effects and help exploit the promising therapeutic potential of VDR ligands, for selected cancers.
###end p 14
###begin title 15
Introduction
###end title 15
###begin title 16
The vitamin D endocrine system
###end title 16
###begin p 17
###xml 358 361 358 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1" ref-type="bibr">[1]</xref>
###xml 502 505 502 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">[2]</xref>
###xml 680 683 680 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib3" ref-type="bibr">[3]</xref>
###xml 871 874 871 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4" ref-type="bibr">[4]</xref>
###xml 377 382 <span type="species:ncbi:9031">Chick</span>
Groundbreaking discoveries of the early 20th century elucidated vitamin D's essential role in calcium and phosphate homeostasis, bone mineralization and enabled major public health advances. The capacity of a novel fat-soluble vitamin that was distinct from vitamins A, B or C, for prevention of experimental Rickets was shown in a seminal study by Mellanby [1]. Subsequently, Chick et al. demonstrated that clinical Rickets could be cured by dietary cod liver oil supplementation or sunlight exposure [2]. The Nobel prize in Chemistry was awarded to Dr Adolf Windaus in 1928, in recognition of his achievement in isolation of vitamin D and demonstration of its steroid structure [3]. In the 1930s, fortification of milk with vitamin D virtually eradicated Rickets from the United States, although it had previously been a highly prevalent crippling disease of childhood [4].
###end p 17
###begin p 18
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 248 249 248 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 287 290 287 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib5" ref-type="bibr">[5]</xref>
###xml 379 380 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 560 561 548 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 563 564 551 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 647 650 635 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6" ref-type="bibr">[6]</xref>
###xml 666 667 650 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 669 670 653 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 793 796 777 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">[7]</xref>
###xml 850 851 830 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 853 854 833 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1087 1090 1067 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8" ref-type="bibr">[8]</xref>
###xml 1362 1365 1342 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">[7]</xref>
###xml 1151 1156 <span type="species:ncbi:9606">human</span>
The mammalian form of vitamin D is a fat-soluble prohormone cholecalciferol (vitamin D3) that may be generated endogenously by ultraviolet light-mediated metabolism of the precursor sterol 7-dehydrocholesterol, in the skin. Alternatively, vitamin D3 may be obtained from dietary sources [5]. This prohormone (cholecalciferol) is hydroxylated to 25-hydroxycholecalciferol (25(OH)D3) by hepatocyte 25-hydroxylase. Further hydroxylation by 1alpha-hydroxylase (CYP27B1), into the main biologically active hormone, 1alpha 25-dihydroxycholecalciferol (1alpha,25-(OH)2 D3 or calcitriol) occurs in the proximal renal tubule in a tightly regulated fashion [6]. 1alpha,25-(OH)2 D3 then acts as a steroid chemical messenger in a diverse target tissues, in what is known as the vitamin D endocrine system [7]. To meet needs of bone mineralization, 1alpha,25-(OH)2 D3 stimulates intestinal calcium and phosphate absorption, bone calcium and phosphate metabolism as well as renal calcium and phosphate reabsorption, by differential effects on osteoblasts, chondrocytes, renal and intestinal epithelia [8]. Furthermore, discovery of VDR expression in diverse normal human tissues including B and T lymphocytes, the hair follicle, muscle, adipose tissue, bone marrow and in cancer cells has widened the perceived scope of the vitamin D endocrine system, beyond bone homeostasis [7].
###end p 18
###begin title 19
###xml 14 15 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
1alpha,25-(OH)2 D3 chemical structure and conformational relationships
###end title 19
###begin p 20
###xml 14 15 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 316 322 312 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 464 465 456 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 467 468 459 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 548 551 540 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cis</italic>
###xml 552 557 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 660 661 648 649 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 663 664 651 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 706 712 694 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 786 792 774 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9 bib10" ref-type="bibr">[9,10]</xref>
1alpha,25-(OH)2 D3, the active form of vitamin D, is a highly flexible molecule with a steroid carbon skeleton, involving 4 fused cyclopentanoperhydro-phenanthrene rings, A-D. Unlike other steroids, the 9-10 carbon bond is broken, thus creating a conformationally flexible molecule in which the "A" ring may rotate (Fig. 1). The molecule is technically classified as a seco-steroid. The spatial arrangements of principal functional components of the 1alpha,25-(OH)2 D3 molecule comprise a hugely important determinant of its biological activities. Cis-trans isomerism influences stability and reactivity. The unusual degree of flexibility within 1alpha,25-(OH)2 D3 enables synthesis of structural analogs (Fig. 1b) that elicit well-defined subsets of the vitamin D response (see below) [9,10].
###end p 20
###begin title 21
Vitamin D transport
###end title 21
###begin p 22
###xml 58 59 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 61 62 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 212 213 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 213 214 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 236 240 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11" ref-type="bibr">[11]</xref>
###xml 275 279 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12" ref-type="bibr">[12]</xref>
###xml 416 417 396 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 419 420 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 465 469 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13" ref-type="bibr">[13]</xref>
###xml 642 646 622 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14" ref-type="bibr">[14]</xref>
###xml 662 663 638 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 665 666 641 642 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 757 758 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 758 759 734 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 790 794 754 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15" ref-type="bibr">[15]</xref>
Normally, only 0.04% of 25(OH)D and 0.4% of 1alpha,25-(OH)2 D3 are free in plasma, the remainder being tightly bound to either a vitamin D transporter protein (DBP) (85-88%; high affinity; dissociation constant [Kd] approximately 1 nM) [11] or albumin (12-15%; low affinity) [12]. Only free unbound vitamin D sterols are considered to be biologically active, since only the free form and not DBP-bound 1alpha,25-(OH)2 D3 induces metabolic responses in target cells [13]. In addition to transport, DBP functions to maintain stable serum stores of vitamin D metabolites, modulate bioavailability and influence responsiveness of some end-organs [14]. 1alpha,25-(OH)2 D3 binds to its "nuclear" receptor (VDR) with high affinity (dissociation constant value of [Kd] approximately 1 nM or lower) [15].
###end p 22
###begin title 23
The vitamin D receptor (VDR)
###end title 23
###begin p 24
###xml 19 20 15 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 22 23 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 80 86 76 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 185 189 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">[16]</xref>
###xml 254 257 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8" ref-type="bibr">[8]</xref>
###xml 330 333 326 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6" ref-type="bibr">[6]</xref>
###xml 406 407 398 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 409 410 401 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 410 414 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr">[17]</xref>
###xml 748 752 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr">[18]</xref>
###xml 754 760 746 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 951 955 943 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19" ref-type="bibr">[19]</xref>
###xml 1156 1160 1148 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">[20]</xref>
Free 1alpha,25-(OH)2 D3 enters the cell and binds the vitamin D receptor (VDR) (Fig. 2a), that may be present in the cytoplasm, nucleus or partitioned between the cytoplasm and nucleus [16]. VDR is an endocrine member of the nuclear receptor superfamily [8] with high structural and ligand-binding homology across various species [6]. Ligands for VDR include bile acid metabolites as well as 1alpha,25-(OH)2 D3[17]. VDR has the same modular structure as other members of the nuclear receptor superfamily, including an N-terminal A/B region, a conserved DNA-binding domain, a flexible hinge region and a moderately conserved ligand-binding pocket that contains a dimerization interface and a ligand-dependent transcriptional activation domain, AF-2 [18] (Fig. 2a and b). Ligand binding induces a conformational change of the AF-2 region that allows dissociation of accessory proteins, exposure of the DNA-binding pocket and recruitment of coactivators [19]. Specific mutations that cause deletions, frameshift mutations, premature stop codons or splice site abnormalities that impede VDR expression or binding activity, effectively suppress key VDR actions [20].
###end p 24
###begin title 25
###xml 14 15 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
1alpha,25-(OH)2 D3/VDR mediated genomic responses
###end title 25
###begin p 26
###xml 18 19 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 21 22 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 320 321 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 323 324 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 350 354 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr">[21]</xref>
###xml 516 520 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib22" ref-type="bibr">[22]</xref>
###xml 785 789 777 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23" ref-type="bibr">[23]</xref>
###xml 915 919 907 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23" ref-type="bibr">[23]</xref>
###xml 935 936 923 924 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 938 939 926 927 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
The 1alpha,25-(OH)2 D3/VDR complex functions to regulate gene transcription through heterodimerization with any of three retinoid X receptor (RXR) isoforms and binds to cognate vitamin D responsive elements (VDREs) in the promoter region of target genes. VDRE structures within promoter regions of primary 1alpha,25-(OH)2 D3 regulated genes can vary [21]. However, the majority of known VDREs show a DR3-type structure comprising a directly repeated arrangement of hexameric binding sites with 3 spacing nucleotides [22]. This arrangement provides the most efficient interface for VDR/RXR heterodimer binding to core VDREs. Subclasses of DR3 VDREs show some sequence variation but their in vivo functionality is proportional to their in vitro binding affinity for VDR-RXR heterodimers [23]. Strongest affinity has been observed among class I DR3-type VDREs, including that present in the osteopontin (OPN) promoter [23]. 1alpha,25-(OH)2 D3 may regulate genes that do not contain VDREs within their promoter regions, through non-genomic VDR actions (see below).
###end p 26
###begin title 27
VDR/VDRE mediated coactivation or corepression of gene transcription
###end title 27
###begin p 28
###xml 47 48 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 50 51 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 167 171 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24" ref-type="bibr">[24]</xref>
###xml 615 619 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr">[25]</xref>
###xml 716 720 712 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19" ref-type="bibr">[19]</xref>
###xml 857 861 853 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr">[26]</xref>
###xml 978 982 974 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr">[27]</xref>
Regulation of gene expression by 1alpha,25-(OH)2 D3 genomic signaling, is dependent upon the ability of VDR/RXR heterodimers to recruit coregulatory protein complexes [24] that may activate or repress target gene expression. Ligand triggered conformational change of VDR-RXR heterodimers results in dissociation of co-repressor proteins such as NCoR (nuclear receptor co-repressor) and facilitates the interaction with members of the CBP/p300 and p160 coactivator families including SRC-1 (steroid receptor coactivators-1), TIF2 (transcriptional intermediary factor 2), and RAC3 (receptor activated coactivators 3) [25]. DRIP (vitamin D receptor-interacting protein) cofactor complexes are also involved in parallel [19]. These coactivators bind ligand-activated VDR, induce a coactivator exchange in the transcriptional complex of VDR-responsive promoters [26] and enables opening of the chromatin structure. These effects create an environment suitable for gene transcription [27].
###end p 28
###begin p 29
###xml 101 102 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 104 105 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 125 129 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28" ref-type="bibr">[28]</xref>
###xml 175 176 167 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 178 179 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 237 241 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib29" ref-type="bibr">[29]</xref>
###xml 281 285 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30" ref-type="bibr">[30]</xref>
###xml 332 333 320 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 335 336 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 452 456 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30" ref-type="bibr">[30]</xref>
###xml 896 897 880 881 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 899 900 883 884 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1323 1327 1307 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib31" ref-type="bibr">[31]</xref>
###xml 1360 1364 1344 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib32" ref-type="bibr">[32]</xref>
###xml 1366 1372 1350 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1420 1421 1400 1401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1423 1424 1403 1404 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1678 1682 1658 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">[16]</xref>
VDR may also repress gene transcription. CYP27B1 catalyzes the metabolic activation of 1alpha,25-(OH)2 D3 from its precursor [28] and is negatively regulated by 1alpha,25-(OH)2 D3, in a cell-lineage-specific and tissue-restricted manner [29]. CYP27B1 and other genes including PTH [30] are thought to be suppressed by 1alpha,25-(OH)2 D3 via negative vitamin D response elements (VDREs). Ligand-activated VDR binds to the 5' half site of negative VDREs [30]. VDR-RXR heterodimers interact with a VDR-interacting repressor (VDIR) at the E-box type element of negative VDREs, comprising a CANNTG-like motif. Such interactions at the E-box induce coregulator switching, involving dissociation of p300 coactivators but association of the histone deacetylator (HDAC) co-repressor complex, resulting in ligand-induced transrepression. Cell or tissue-specific transrepression of CYP27B1 by 1alpha,25-(OH)2 D3 may involve multiple VDREs located in more distal promoter regions that enhance chromatin looping and interactions with protein super complexes of differing transcriptional abilities. Other mechanisms of transrepression involve the association between WINAC (Williams syndrome transcription factor (WSTF) including nucleosome assembly complex), a multifunctional, ATP-dependent chromatin-remodelling complex and chromatin [31] and VDR-induced DNA methylation [32] (Fig. 3). These actions of the classical 1alpha,25-(OH)2 D3 genomic response modulate synthesis and accumulation of new proteins and invoke appropriate cellular responses, over intervals of hours or days. These events may also be suppressed by protein synthesis inhibitors, such as actinomycin D or cycloheximide [16].
###end p 29
###begin title 30
###xml 14 15 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
1alpha,25-(OH)2 D3-mediated rapid or non-genomic responses
###end title 30
###begin p 31
###xml 66 67 62 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 69 70 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 248 252 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib33" ref-type="bibr">[33]</xref>
###xml 292 296 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">[34]</xref>
###xml 333 337 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35" ref-type="bibr">[35]</xref>
###xml 353 354 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 356 357 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 378 380 370 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 480 484 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36" ref-type="bibr">[36]</xref>
###xml 496 498 488 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 541 545 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib37" ref-type="bibr">[37]</xref>
###xml 597 599 589 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 626 633 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib37 bib38" ref-type="bibr">[37,38]</xref>
###xml 792 796 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib33" ref-type="bibr">[33]</xref>
###xml 893 894 881 882 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 896 897 884 885 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 936 940 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib39" ref-type="bibr">[39]</xref>
###xml 1022 1023 1006 1007 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1025 1026 1009 1010 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1163 1167 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib40" ref-type="bibr">[40]</xref>
###xml 457 460 <span type="species:ncbi:10116">rat</span>
Notwithstanding the strong, non-covalent binding of 1alpha,25-(OH)2 D3 to its cognate receptor, this active sterol can also elicit rapid responses in target cells of the vitamin D endocrine system. Effects include generation of calcium or ion flux [33], induction of second messenger systems [34] and activation of cytosolic kinases [35]. 1alpha,25-(OH)2 D3 may promote rapid Ca2+ influx from the extracellular space through voltage-independent channels in rat osteosarcoma cells [36], release Ca2+ from intra-cellular stores in osteoblasts [37] and activate protein kinase pathways that may be Ca2+-dependent or -independent [37,38]. These effects occur rapidly within minutes and are considered incompatible with mechanisms involving alterations in gene transcription and protein synthesis [33]. Involvement of VDR in this pathway remains controversial, since rapid actions of 1alpha,25-(OH)2 D3 may be invoked in cells that lack VDR [39]. However, in various cell types rapid responses can be mediated by 1alpha,25-(OH)2 D3 acting through a population of classical VDR molecules acting outside the cell nucleus, associated with caveolae of the plasma membrane [40].
###end p 31
###begin p 32
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 196 202 196 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9 bib10" ref-type="bibr">[9,10]</xref>
Importantly, analogs of different vitamin D isomers that are locked in cis- or trans-conformations have been synthesized which can preferentially elicit rapid non-genomic and/or genomic responses [9,10].
###end p 32
###begin title 33
###xml 14 15 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
1alpha,25-(OH)2 D3 dual regulation of gene expression by genomic and rapid non-genomic pathways
###end title 33
###begin p 34
###xml 116 117 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 119 120 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 185 192 181 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib41 bib42" ref-type="bibr">[41,42]</xref>
###xml 218 219 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 221 222 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 328 332 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib43" ref-type="bibr">[43]</xref>
###xml 355 359 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib44" ref-type="bibr">[44]</xref>
###xml 450 451 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 453 454 441 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 481 485 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib45" ref-type="bibr">[45]</xref>
###xml 559 560 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 562 563 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 588 592 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib41" ref-type="bibr">[41]</xref>
###xml 608 609 588 589 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 611 612 591 592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 751 755 731 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib46" ref-type="bibr">[46]</xref>
###xml 795 796 771 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 798 799 774 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 928 932 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib38" ref-type="bibr">[38]</xref>
###xml 986 990 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib47" ref-type="bibr">[47]</xref>
###xml 1027 1031 1003 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib48" ref-type="bibr">[48]</xref>
###xml 1201 1202 1173 1174 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1204 1205 1176 1177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1268 1271 1240 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">[7]</xref>
There is compelling evidence that the rapid non-genomic activation of signal transduction pathways by 1alpha,25-(OH)2 D3 can interact with and modulate VDR-dependent gene transcription [41,42]. While the 1alpha,25-(OH)2 D3-liganded RXR-VDR heterocomplex selectively recognizes VDREs in the promoter regions of osteopontin (OPN) [43] and osteocalcin (OCN) [44] genes, the steady state levels of OPN and OCN mRNA can also be modulated by 1alpha,25-(OH)2 D3 rapid non-genomic actions [45]. Furthermore, antagonism of the non-genomic pathway blocks 1alpha,25-(OH)2 D3-mediated OCN expression [41]. 1alpha,25-(OH)2 D3 rapid activation of cytosolic kinases may phosphorylate critical coactivators resulting in modulation of VDR-dependent gene transcription [46]. By non-genomic actions, 1alpha,25-(OH)2 D3 can modulate a repertoire of cytosolic kinases and second messenger systems that show some level of cell- or tissue-specificity [38], e.g. activation of phospholipase A2 in chondrocytes [47] and protein kinase A in enterocytes [48]. By cross-talk with VDR/VDRE regulation of gene transcription, these membrane-mediated kinase cascades may influence cell-specific biological responses to 1alpha,25-(OH)2 D3, involved diverse physiological and pathobiological processes [7].
###end p 34
###begin title 35
Tissue- and cell-specificity of vitamin D biological effects
###end title 35
###begin p 36
###xml 52 53 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 55 56 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 259 260 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 262 263 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 263 267 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib49" ref-type="bibr">[49]</xref>
###xml 341 342 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 344 345 332 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 493 494 477 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 496 497 480 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 547 551 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30" ref-type="bibr">[30]</xref>
###xml 606 610 587 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib50" ref-type="bibr">[50]</xref>
###xml 639 643 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib51" ref-type="bibr">[51]</xref>
###xml 686 690 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib52" ref-type="bibr">[52]</xref>
###xml 734 738 715 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib53" ref-type="bibr">[53]</xref>
###xml 781 785 762 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib54" ref-type="bibr">[54]</xref>
Most tissues express the receptor for 1alpha,25-(OH)2 D3 (VDR) and renal tubules, skin, bone, brain, breast, colon and prostate also contain the enzyme CYP27B1, required for converting the major circulating metabolite of vitamin D, [25(OH)D] to 1alpha,25-(OH)2 D3[49]. Notwithstanding the wide distribution of VDR and CYP27B1, 1alpha,25-(OH)2 D3 shows highly tissue-specific functional effects on hormone secretion, immune function, cell differentiation and growth. For example, 1alpha,25-(OH)2 D3 inhibits PTH secretion in the parathyroid glands [30] but stimulates pancreatic beta-cell insulin secretion [50], inhibits adaptive immunity [51] but enhances some innate immune responses [52], inhibits differentiation of B lymphocytes [53] but enhances keratinocyte differentiation [54].
###end p 36
###begin p 37
###xml 14 15 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 105 106 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 108 109 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 165 169 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib55" ref-type="bibr">[55]</xref>
###xml 366 367 354 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 369 370 357 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 370 374 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib56" ref-type="bibr">[56]</xref>
###xml 443 444 427 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 446 447 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 487 491 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib57" ref-type="bibr">[57]</xref>
###xml 509 513 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib58" ref-type="bibr">[58]</xref>
###xml 632 633 612 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 635 636 615 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 712 716 692 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib59" ref-type="bibr">[59]</xref>
###xml 773 777 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib59" ref-type="bibr">[59]</xref>
###xml 802 806 782 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib60" ref-type="bibr">[60]</xref>
###xml 887 891 867 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib61" ref-type="bibr">[61]</xref>
###xml 1004 1008 984 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib62" ref-type="bibr">[62]</xref>
1alpha,25-(OH)2 D3-mediated growth effects may show similar cell-specificity. For example, 1alpha,25-(OH)2 D3 has antiproliferative effects in some neoplastic cells [55] but induces a spectrum of growth responses in others. The PC-3 and DU-145 prostate cancer cell lines for example are not significantly inhibited by physiologically relevant doses of 1alpha,25-(OH)2 D3[56]. Furthermore, at low or physiological concentrations, 1alpha,25-(OH)2 D3 may promote proliferation of monocytes [57] or keratinocytes [58]. Effects upon anchorage-independent growth and invasion may show similar cell-specificity. For example, 1alpha,25-(OH)2 D3 or analogs inhibited anchorage-independent growth of prostate cancer cells [59] and suppressed invasion through Matrigel by these cells [59] and neuroblastoma cells [60]. Conversely, vitamin D or analogs may also enhance anchorage-independent growth [61] and promote 12-O-tetradecanoylphorbol-13-acetate (TPA) induced neoplastic transformation in JB6 epidermal cells [62].
###end p 37
###begin p 38
###xml 190 191 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 193 194 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
These observations do not support uniform growth or other biological responses to vitamin D exposure. Rather, cell- or tissue-specific processes, could modulate the initiating 1alpha,25-(OH)2 D3 signal to provide different functional outcomes.
###end p 38
###begin title 39
###xml 34 35 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 37 38 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
The Yin and Yang of 1alpha,25-(OH)2 D3 growth regulatory signaling
###end title 39
###begin p 40
###xml 69 70 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 72 73 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 290 294 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib63" ref-type="bibr">[63]</xref>
###xml 338 339 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 341 342 333 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 428 432 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib64" ref-type="bibr">[64]</xref>
Expression profiling has identified diverse targets of 1alpha,25-(OH)2 D3 non-genomic or genomic actions including G-coupled receptors, inter- and intra-cellular signaling genes, cell-cycle regulators, metabolic function moeties, extracellular matrix components and cell adhesion molecules [63]. From within these networks, 1alpha,25-(OH)2 D3 not only regulates bone mineralization but also modulates growth and differentiation [64]. Such diversity of biological effect could be achieved in part through genomic/non-genomic cross-talk, molecular networks or transcriptomes implicated in lineage specialization or effects on target genes with context-specific functions.
###end p 40
###begin p 41
###xml 117 124 117 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib65 bib66" ref-type="bibr">[65,66]</xref>
###xml 203 204 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 206 207 202 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 225 229 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr">[26]</xref>
###xml 257 264 253 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib45 bib67" ref-type="bibr">[45,67]</xref>
###xml 358 362 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib45" ref-type="bibr">[45]</xref>
###xml 447 451 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib68" ref-type="bibr">[68]</xref>
###xml 588 592 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib69" ref-type="bibr">[69]</xref>
###xml 608 609 600 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 611 612 603 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 796 800 788 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr">[26]</xref>
###xml 900 901 888 889 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 903 904 891 892 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 976 980 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib70" ref-type="bibr">[70]</xref>
###xml 1062 1064 1050 1052 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1173 1177 1161 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67" ref-type="bibr">[67]</xref>
###xml 1253 1257 1241 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67" ref-type="bibr">[67]</xref>
###xml 1385 1389 1373 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib71" ref-type="bibr">[71]</xref>
###xml 844 847 <span type="species:ncbi:10116">rat</span>
Within such modular networks, osteopontin (OPN) and E-cadherin play important roles in growth responses to vitamin D [65,66]. Osteopontin (OPN) is a key vitamin D target gene, regulated by 1alpha,25-(OH)2 D3-mediated genomic [26] and non-genomic mechanisms [45,67]. OPN is an extracellular matrix glycophosphoprotein implicated in osteoblast differentiation [45] but is also a central effector of vitamin D - mediated anchorage-independent growth [68]. OPN may abrogate the adhesion requirement for cell growth and enhance cell invasion through Matrigel by activation of Ran GTPase (RAN) [69]. 1alpha,25-(OH)2 D3 transcriptional regulation of OPN involves VDR/RXR heterodimer binding and recruitment of coregulators including SRC-1, -2, -3, CBP, p300 and DRIP205 to VDREs within the OPN promoter [26]. Mutation at one or both VDRE sites in the rat OPN promoter substantively suppresses 1alpha,25-(OH)2 D3-mediated transcription of a OPN-promoter luciferase reporter construct [70]. However, OPN mRNA may also be activated by VDR non-genomic actions, involving Ca2+-influx and rapid activation of the small GTPAse, RhoA and its effector, Rho-associated coiled kinase (ROCK) [67]. Effects of this non-genomic pathway on OPN protein expression are unclear [67]. RhoA-ROCK activation of OPN mRNA in smooth muscle cells is Erk dependent and may be suppressed by the MEK1 inhibitor, PD98059 [71].
###end p 41
###begin p 42
###xml 39 40 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 42 43 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 70 74 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67" ref-type="bibr">[67]</xref>
###xml 165 172 158 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib72 bib73" ref-type="bibr">[72,73]</xref>
###xml 606 610 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib74" ref-type="bibr">[74]</xref>
###xml 626 627 600 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 629 630 603 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 705 707 679 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 908 912 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67" ref-type="bibr">[67]</xref>
###xml 1030 1031 997 998 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1033 1034 1000 1001 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
E-cadherin is induced by 1alpha,25-(OH)2 D3 non-genomic rapid actions [67] and suppresses cell growth, partly by inhibition of beta-catenin transcriptional activity [72,73]. Free beta-catenin that is sequestered by E-cadherin, is rapidly phosphorylated by glycogen synthase kinase3beta (GSK3beta) in the adenomatous polyposis coli (APC)/axin/GSK-3beta/casein kinase I complex and is subsequently ubiquitinated and degraded. Loss of this function enables beta-catenin accumulation and translocation to the nucleus where it modulates the expression of Tcf/Lef-1-target genes implicated in cell proliferation [74]. 1alpha,25-(OH)2 D3 induction of E-cadherin involves transcription-independent promotion of Ca2+-influx and consequent activation of RhoA-ROCK signaling. Subsequent to these events, induction of p38/MAPK-MSK1 signaling upregulates E-cadherin and inhibits beta-catenin/Tcf transcriptional activity [67]. Hence, OPN and E-cadherin are functionally antagonistic growth regulatory genes that are modulated by 1alpha,25-(OH)2 D3 through overlapping but distinct molecular mechanisms.
###end p 42
###begin title 43
###xml 82 83 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 85 86 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
Growth signaling through E-cadherin and OPN: functional outcomes of 1alpha,25-(OH)2 D3 treatment
###end title 43
###begin p 44
###xml 102 106 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib75" ref-type="bibr">[75]</xref>
###xml 179 186 176 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib76 bib77" ref-type="bibr">[76,77]</xref>
###xml 308 312 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib78" ref-type="bibr">[78]</xref>
###xml 324 328 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib76" ref-type="bibr">[76]</xref>
###xml 342 346 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib68" ref-type="bibr">[68]</xref>
E-cadherin and OPN are reciprocally regulated through beta-catenin/Tcf and related signaling pathways [75] to provide high and low levels respectively, in quiescent normal tissue [76,77]. Disturbance of this equilibrium in early stages of multistep tumorigenesis may have phenotypic effects on cell adhesion [78], migration [76] and invasion [68]. Aberrant expression of these genes in early tumorigenesis may influence the subsequent development of abnormal molecular circuitry in evolving cancer cells.
###end p 44
###begin p 45
###xml 78 79 74 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 81 82 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 220 224 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib70" ref-type="bibr">[70]</xref>
###xml 566 570 559 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib79" ref-type="bibr">[79]</xref>
###xml 858 862 851 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib75" ref-type="bibr">[75]</xref>
###xml 975 979 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib80" ref-type="bibr">[80]</xref>
###xml 1017 1018 1006 1007 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1020 1021 1009 1010 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
To investigate involvement of the E-cadherin/OPN equilibrium in 1alpha,25-(OH)2 D3 growth control, Xu et al. used parental cell lines and stably transformed subclones with variable constitutive expression of these genes [70]. Parental R37 mammary cells highly express E-cadherin, have an epithelial-like morphology, have low levels of Tcf-1 indicative of low level beta-catenin signaling activity and weak expression of OPN. Subclones were raised by stable transfection of R37 cells with metastatic tumor DNA fragments (R37 Met-DNA; [C9] cells) that upregulates OPN [79]. Subclones were also raised by transfection of parental R37 cells with OPN cDNA in sense or antisense orientations respectively, in expression vectors. R37 Met-DNA [C9] cells express high levels of OPN and Tcf-1, low levels of E-cadherin, have a spindle-like morphology and are invasive [75]. In these cells, OPN is considered to be the direct effector of Met-DNA, in promotion of invasion or metastasis [80]. In this model system, 1alpha,25-(OH)2 D3 and novel A-ring modified vitamin D analogs influenced the balance of these antagonistic VDR-dependent signals. All treatments upregulated E-cadherin, suppressed beta-catenin transcriptional activity and beta-catenin nuclear localization, consistent with growth-inhibition. However, all treatments also upregulated OPN that may be implicated in neoplastic transformation and invasion.
###end p 45
###begin p 46
###xml 84 85 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 87 88 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 336 340 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib70" ref-type="bibr">[70]</xref>
###xml 484 485 476 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 487 488 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 584 585 572 573 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 587 588 575 576 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
Although molecular cross-talk was observed, growth effects induced by 1alpha,25-(OH)2 D3 or analogs appeared dependent upon the constitutive balance of these functionally antagonistic molecules, in target cells. VDR ligands significantly increased migration or invasion only in those cells with high constitutive OPN and low E-cadherin [70]. This finding suggests that the pre-treatment activity state of antagonistic VDR-dependent molecules may influence cell-specific 1alpha,25-(OH)2 D3 growth responses. These fundamental studies may provide greater understanding of 1alpha,25-(OH)2 D3 growth effects relating to cancer, in whole animal studies as well as clinical or epidemiological surveys.
###end p 46
###begin title 47
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Tumorigenesis in VDR knockout mice
###end title 47
###begin p 48
###xml 92 93 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 95 96 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 274 278 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib81" ref-type="bibr">[81]</xref>
###xml 410 414 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib82" ref-type="bibr">[82]</xref>
###xml 525 529 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib83" ref-type="bibr">[83]</xref>
###xml 670 672 666 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 687 691 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib83" ref-type="bibr">[83]</xref>
###xml 1190 1194 1186 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib83" ref-type="bibr">[83]</xref>
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">Mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
Development of a null mouse model has provided an important tool for study of 1alpha,25-(OH)2 D3/VDR functional roles in tumor biology. VDR null mice appear developmentally normal at birth but manifest growth abnormalities, alopecia and infertility from the time of weaning [81]. Mice deficient in VDR or key components of the vitamin D synthetic pathway do not manifest any increase of sporadic tumorigenesis [82]. However, VDR ablation alters susceptibility to chemically induced carcinogenesis in a tissue-specific manner [83]. Administration of DMBA together with medroxprogesterone induced increased formation of skin tumors and mammary hyperplasia in VDR knockout vs. control mice [83]. Although differences were observed in development of thymic lymphomas, lymphoblastic leukemias and mammary tumor histopathology, VDR status did not affect overall non-epidermal tumor incidence. No effects were observed on tumorigenesis in the ovary, uterus, liver or lung, despite expression of the VDR in these tissues. These findings provide strong evidence that VDR signaling alters chemically induced carcinogenesis in a manner that is tissue-specific but unrelated to VDR expression, in vivo [83].
###end p 48
###begin title 49
###xml 24 29 <span type="species:ncbi:9606">human</span>
Vitamin D exposures and human cancer risk
###end title 49
###begin p 50
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib84" ref-type="bibr">[84]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib85" ref-type="bibr">[85]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib86" ref-type="bibr">[86]</xref>
###xml 373 377 373 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib87" ref-type="bibr">[87]</xref>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib88" ref-type="bibr">[88]</xref>
###xml 538 545 538 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib89 bib90" ref-type="bibr">[89,90]</xref>
###xml 608 615 608 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib91 bib92" ref-type="bibr">[91,92]</xref>
###xml 673 680 673 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib93 bib94" ref-type="bibr">[93,94]</xref>
###xml 803 810 803 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib95 bib96" ref-type="bibr">[95,96]</xref>
###xml 825 829 825 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib97" ref-type="bibr">[97]</xref>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib98" ref-type="bibr">[98]</xref>
###xml 1106 1110 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib99" ref-type="bibr">[99]</xref>
###xml 1118 1130 <span type="species:ncbi:9606">participants</span>
Associations between sunlight exposure, dietary histories and tumor incidence in various epidemiological surveys imply an important role for vitamin D in lifetime cancer risk and/or survival [84]. For example, mortality from colon cancer was found to be higher in geographical regions of the United States with low sunlight exposure [85] while decreased colon [86], breast [87] and prostate cancer risk [88] were reported in high sunlight areas. Inverse relationships between dietary vitamin D intake and breast cancer have been reported [89,90] although findings for colorectal cancer appeared inconsistent [91,92] and no clear associations were found for prostate cancer [93,94]. The relationship between sunlight exposure and risk of lymphoma has also been controversial. Studies have shown positive [95,96], inconsistent [97] or inverse [98] relationships between estimated solar ultraviolet exposure and non-Hodgkins lymphoma (NHL). No clear association between dietary intake of vitamin D and risk of NHL, diffuse large B-cell lymohoma, chronic lymphocytic leukemia or follicular lymphoma were found [99]. Study participants' histories of sun exposure or intake of foods that are high in vitamin D may however be subject to systematic recall error and associated bias.
###end p 50
###begin p 51
###xml 121 126 121 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib100" ref-type="bibr">[100]</xref>
###xml 251 260 251 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib101 bib102" ref-type="bibr">[101,102]</xref>
###xml 462 467 462 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib103" ref-type="bibr">[103]</xref>
###xml 540 545 540 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib103" ref-type="bibr">[103]</xref>
###xml 590 599 590 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib104 bib105" ref-type="bibr">[104,105]</xref>
###xml 626 635 626 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib106 bib107 bib108" ref-type="bibr">[106&#8211;108]</xref>
###xml 906 911 906 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib109" ref-type="bibr">[109]</xref>
###xml 1077 1082 1077 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib110" ref-type="bibr">[110]</xref>
###xml 1331 1336 1331 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib108" ref-type="bibr">[108]</xref>
###xml 237 242 <span type="species:ncbi:9606">women</span>
###xml 247 250 <span type="species:ncbi:9606">men</span>
The vitamin D metabolite 25-OHD has a long half-life and serum levels may provide a robust biomarker of vitamin D status [100]. Subjects with high levels of 25-OHD were found to have a lower incidence of colorectal cancer (CRC), in both women and men [101,102], Freedman and colleagues confirmed an inverse association between serum 25-OHD levels and CRC risk and demonstrated that the highest percentile serum 25-OHD levels had a CRC relative risk (RR) of 0.28 [103]. No clear association with total cancer mortality was observed, however [103]. Associations between 25-OHD levels, breast [104,105] and total prostate cancer [106-108] have been inconsistent. In a nested case-control study involving 270 incident lymphoid cancer cases and 538 controls from a cohort of 29,133 Finnish male smokers, serum 25-OHD levels were not associated with the risk of overall lymphoid cancers, NHL or multiple myeloma [109]. However, high serum serum 25-OHD levels were associated with increased risk of pancreatic cancer in 200 Finnish cases and 400 controls, from this same total cohort [110]. In a further nested case-control study, high prediagnostic serum 25-OHD levels had increased risk of aggressive prostate cancer in 749 cases and 781 control subjects from the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial [108].
###end p 51
###begin p 52
###xml 157 162 157 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib111" ref-type="bibr">[111]</xref>
###xml 396 401 396 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib112" ref-type="bibr">[112]</xref>
###xml 434 439 434 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib113" ref-type="bibr">[113]</xref>
In the nested case-control study design, non-diseased subjects from whom the controls are selected may not be fully representative of the healthy population [111]. In a prospective cohort study of >700 apparently healthy adults from the Linxian region of China, higher serum 25(OH)D concentrations were associated with significantly increased risk of development of esophageal squamous dysplasia [112] and invasive squamous carcinoma [113].
###end p 52
###begin p 53
###xml 281 290 281 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib102 bib103" ref-type="bibr">[102,103]</xref>
###xml 384 389 384 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib112" ref-type="bibr">[112]</xref>
###xml 400 405 400 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib113" ref-type="bibr">[113]</xref>
###xml 425 430 425 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib110" ref-type="bibr">[110]</xref>
###xml 461 466 461 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib108" ref-type="bibr">[108]</xref>
###xml 564 565 560 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 567 568 563 564 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
These epidemiological studies show positive and negative associations between vitamin D status and common solid cancers in various populations and allude to tissue-specificity of effect. At present, any chemopreventive benefits of higher serum 25(OH)D levels for colorectal cancer [102,103] may require to be weighed against potential increased risks of esophageal squamous dysplasia [112] or cancer [113], pancreatic cancer [110] or aggressive prostate cancer [108]. Within interacting molecular networks that influence tissue-specific responses to 1alpha,25-(OH)2 D3, a dynamic equilibrium of positive or negative growth signals may determine ultimate outcomes, although key molecules can have specific effects upon development of neoplastic phenotype.
###end p 53
###begin title 54
Tissue-specific VDR operational networks and cancer risk
###end title 54
###begin p 55
###xml 128 136 128 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib77 bib114" ref-type="bibr">[77,114]</xref>
###xml 429 434 429 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib115" ref-type="bibr">[115]</xref>
###xml 463 468 463 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib116" ref-type="bibr">[116]</xref>
###xml 815 820 815 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib117" ref-type="bibr">[117]</xref>
###xml 984 989 984 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib118" ref-type="bibr">[118]</xref>
###xml 1083 1088 1083 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib119" ref-type="bibr">[119]</xref>
###xml 1113 1118 1113 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib120" ref-type="bibr">[120]</xref>
###xml 1233 1238 1233 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib113" ref-type="bibr">[113]</xref>
###xml 1272 1273 1268 1269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1275 1276 1271 1272 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1377 1381 1373 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib69" ref-type="bibr">[69]</xref>
###xml 1598 1607 1594 1603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib121 bib122 bib123 bib124" ref-type="bibr">[121&#8211;124]</xref>
###xml 1762 1774 1758 1770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67 bib108 bib110" ref-type="bibr">[67,108,110]</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
The VDR growth regulatory equilibrium involving E-cadherin and OPN is disturbed during stepwise evolution of many human cancers [77,114] although there are important tissue-specific differences. In the colon for example, adenomatous polyps represent the commonest identifiable premalignant lesion. These colonic adenomas have E-cadherin/OPN expression patterns resembling that of normal mucosa, namely preservation of E-cadherin [115] and low or undetectable OPN [116]. Hence, in these lesions, high level serum [25(OH)D] could further increase E-cadherin tumor suppressor activity, set against low level OPN with an overall effect of growth restraint. By this rationale, persistently high serum [25(OH)D] could impede neoplastic progression of colonic adenomas which are common in asymptomatic Western populations [117], with ultimate reduction of CRC incidence. Conversely, preneoplastic squamous mucosal hyperplasia or dysplasia are common in high risk areas for esophageal cancer [118]. Unlike colonic adenomas, these lesions are characterised by early suppression of E-cadherin [119] and upregulation of OPN [120]. In such populations, higher serum [25(OH)D] levels are associated with increased esophageal squamous cancer risk [113]. Potentially, high 1alpha,25-(OH)2 D3 exposure could enhance the predominance of OPN growth-promoting signals and associated Ran activity [69] in these lesions, beyond the threshold level required for invasion and neoplastic progression. Neoplasms of the pancreas and prostate are characterised by similar disequilibrium involving low E-cadherin and high OPN [121-124] which could potentially be related to the direct associations between serum [25(OH)D] levels and risks of pancreatic cancer or aggressive prostate cancer [67,108,110].
###end p 55
###begin p 56
###xml 30 31 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 33 34 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 359 360 351 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 362 363 354 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 196 201 <span type="species:ncbi:9606">human</span>
Tissue-specific 1alpha,25-(OH)2 D3 growth responses may involve complex non-genomic/genomic cross-talk and modulation of downstream signals by distinct lineage-specific expression patterns of the human transcriptome. However, the E-cadherin/OPN expression balance may provide a useful biologically based marker of this complexity, implicated in 1alpha,25-(OH)2 D3 growth responses.
###end p 56
###begin title 57
Towards conditional targeting strategies
###end title 57
###begin p 58
The above studies address fundamental mechanisms and link tissue-specific differences of VDR growth regulatory networks, particularly involving OPN and E-cadherin to epidemiological associations between serum [25(OH)D] levels and cancer.
###end p 58
###begin p 59
###xml 42 43 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 45 46 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 89 92 85 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">[7]</xref>
###xml 166 170 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67" ref-type="bibr">[67]</xref>
###xml 186 187 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 189 190 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 227 229 219 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 503 507 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67" ref-type="bibr">[67]</xref>
###xml 557 558 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 560 561 545 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 599 601 584 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 714 715 695 696 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 717 718 698 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 822 826 803 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67" ref-type="bibr">[67]</xref>
###xml 901 905 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib67" ref-type="bibr">[67]</xref>
Although genomic effects of 1alpha,25-(OH)2 D3 are partly implicated in induction of OPN [7], they appear dispensible for induction of E-cadherin in colorectal cells [67]. 1alpha,25-(OH)2 D3 induces transcription-independent Ca2+ influx and activation of RhoA-ROCK, in the presence VDR. Thus activated, RhoA-ROCK upregulates p38 MAPK and MSK1, leading to substantive induction of E-cadherin mRNA and protein, inhibition of beta-catenin/Tcf transcriptional activity and suppression of cell proliferation [67]. OPN mRNA may also be regulated by 1alpha,25-(OH)2 D3 through transcription-independent, Ca2+-dependent RhoA/ROCK activation although the response appears less robust than that of E-cadherin. 1alpha,25-(OH)2 D3 induced 30-fold induction of E-cadherin mRNA but less than 10-fold upregulation of OPN mRNA within 8 h [67]. Downstream of Rho/ROCK, p38/MSK1 is required for induction of E-cadherin [67]. Conversely, in smooth muscle cells RhoA/ROCK activation of ERK is implicated in upregulation of OPN mRNA.
###end p 59
###begin p 60
###xml 82 83 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 85 86 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 93 95 89 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
Additional work is required to explore mechanistic issues involving 1alpha,25-(OH)2 D3 rapid vs. genomic effects, regulation of signaling kinases and differential activation of E-cadherin/OPN growth regulatory genes. Rational design of combination therapies that allows activation of E-cadherin without upregulation of OPN may be a useful target for tissue-specific pharmacotherapeutics, particularly for preneoplastic states characterised by high constitutive OPN. Such future advances may provide a rationale for improved prevention and treatment of different cancers, through VDR mediated growth control.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
###xml 199 205 199 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 257 263 257 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 357 363 357 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 363 368 363 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib126" ref-type="bibr">[126]</xref>
The authors gratefully acknowledge the financial support of the Wellcome Trust (Grant No GR069313AIA) for grant funding and are greatly obliged to Dr GH Posner Johns Hopkins University Baltimore for Fig. 1, Boston University, MA for permission to reproduce Fig. 2b and to Dr CS Johnston, Roswell Park Cancer Institute, New York, for permission to reproduce Fig. 3[126].
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
An experimental investigation on rickets
###end article-title 64
###begin article-title 65
###xml 28 35 <span type="species:ncbi:9606">infants</span>
The aetiology of rickets in infants: prophylactic and curative observations at the Vienna University Kinderklinik
###end article-title 65
###begin article-title 66
Nobel prize winners in chemistry
###end article-title 66
###begin article-title 67
Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease
###end article-title 67
###begin article-title 68
Overview of general physiologic features and functions of vitamin D
###end article-title 68
###begin article-title 69
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Vitamin D and human health: lessons from vitamin D receptor null mice
###end article-title 69
###begin article-title 70
Minireview: vitamin D receptor: new assignments for an already busy receptor
###end article-title 70
###begin article-title 71
The vitamin D hormone and its nuclear receptor: molecular actions and disease states
###end article-title 71
###begin article-title 72
Antiproliferative hybrid analogs of the hormone 1alpha,25-dihydroxyvitamin D (3): design, synthesis, and preliminary biological evaluation
###end article-title 72
###begin article-title 73
Rapid and genomic biological responses are mediated by different shapes of the agonist steroid hormone, 1alpha, 25(OH)2 vitamin D3
###end article-title 73
###begin article-title 74
###xml 91 96 <span type="species:ncbi:9606">human</span>
Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP)
###end article-title 74
###begin article-title 75
Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein
###end article-title 75
###begin article-title 76
Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes
###end article-title 76
###begin article-title 77
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein
###end article-title 77
###begin article-title 78
Molecular recognition and structure-activity relations
###end article-title 78
###begin article-title 79
Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model
###end article-title 79
###begin article-title 80
Vitamin D receptor as an intestinal bile acid sensor
###end article-title 80
###begin article-title 81
The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand
###end article-title 81
###begin article-title 82
Increasing the complexity of coactivation in nuclear receptor signaling
###end article-title 82
###begin article-title 83
New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model
###end article-title 83
###begin article-title 84
Critical analysis of 1alpha 25-dihydroxy vitamin D3 response elements
###end article-title 84
###begin article-title 85
Mechanisms of nuclear signalling by vitamin D3. Interplay with retinoid and thyroid hormone signalling
###end article-title 85
###begin article-title 86
All natural DR3-type vitamin D response elements show a similar functionality in vitro
###end article-title 86
###begin article-title 87
Combinatorial control of gene expression by nuclear receptors and coregulators
###end article-title 87
###begin article-title 88
Co-activators and co-repressors in the integration of transcriptional responses
###end article-title 88
###begin article-title 89
1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts
###end article-title 89
###begin article-title 90
Steroid receptor coactivator-1 is a histone acetyltransferase
###end article-title 90
###begin article-title 91
Evidence for a new kidney-produced hormone, 1,25-dihydroxycholecalciferol, the proposed biologically active form of vitamin D
###end article-title 91
###begin article-title 92
Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment
###end article-title 92
###begin article-title 93
###xml 17 22 <span type="species:ncbi:9606">human</span>
Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3
###end article-title 93
###begin article-title 94
Ligand-induced transrepression by VDR through association of WSTF with acetylated histones
###end article-title 94
###begin article-title 95
###xml 57 62 <span type="species:ncbi:9606">human</span>
1alpha,25(OH)2 D3-induced DNA methylation suppresses the human CYP27B1 gene
###end article-title 95
###begin article-title 96
1 alpha,25(OH)2 vitamin D3: a steroid hormone capable of producing pleiotropic receptor-mediated biological responses by both genomic and nongenomic mechanisms
###end article-title 96
###begin article-title 97
Dual 1,25-dihydroxyvitamin D3 signal response pathways in osteoblasts: cross-talk between genomic and membrane-initiated pathways
###end article-title 97
###begin article-title 98
Rapid vitamin D-dependent PKC signaling shares features with estrogen-dependent PKC signaling in cartilage and bone
###end article-title 98
###begin article-title 99
###xml 85 88 <span type="species:ncbi:10116">rat</span>
Vitamin D3 metabolites modulate dihydropyridine-sensitive calcium currents in clonal rat osteosarcoma cells
###end article-title 99
###begin article-title 100
Phospholipase C beta and membrane action of calcitriol and estradiol
###end article-title 100
###begin article-title 101
Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R,25(OH)2-vitamin D3
###end article-title 101
###begin article-title 102
###xml 152 157 <span type="species:ncbi:10090">mouse</span>
Vitamin D receptor is not required for the rapid actions of 1,25-dihydroxyvitamin D3 to increase intracellular calcium and activate protein kinase C in mouse osteoblasts
###end article-title 102
###begin article-title 103
The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha 25(OH)2-vitamin D3 in vivo and in vitro
###end article-title 103
###begin article-title 104
The rapid nongenomic actions of 1 alpha 25-dihydroxyvitamin D3 modulate the hormone-induced increments in osteocalcin gene transcription in osteoblast-like cells
###end article-title 104
###begin article-title 105
Rapid effects of 1,25(OH)2 vitamin D3 on signal transduction systems in colonic cells
###end article-title 105
###begin article-title 106
###xml 142 147 <span type="species:ncbi:10090">mouse</span>
Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression
###end article-title 106
###begin article-title 107
###xml 39 44 <span type="species:ncbi:9606">human</span>
Baculovirus-mediated expression of the human vitamin D receptor. Functional characterization, vitamin D response element interactions, and evidence for a receptor auxiliary factor
###end article-title 107
###begin article-title 108
1 alpha, 25-dihydroxyvitamin D3-induced changes in intracellular pH in osteoblast-like cells modulate gene expression
###end article-title 108
###begin article-title 109
Enhancement of VDR-mediated transcription by phosphorylation: correlation with increased interaction between the VDR and DRIP205, a subunit of the VDR-interacting protein coactivator complex
###end article-title 109
###begin article-title 110
Plasma membrane requirements for 1alpha, 25(OH)2 D3 dependent PKC signaling in chondrocytes and osteoblasts
###end article-title 110
###begin article-title 111
###xml 132 137 <span type="species:ncbi:9031">chick</span>
24,25-Dihydroxyvitamin D3 suppresses the rapid actions of 1, 25-dihydroxyvitamin D3 and parathyroid hormone on calcium transport in chick intestine
###end article-title 111
###begin article-title 112
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
Co-expression of CYP27B1 enzyme with the 1.5kb CYP27B1 promoter-luciferase transgene in the mouse
###end article-title 112
###begin article-title 113
1,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion
###end article-title 113
###begin article-title 114
Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions
###end article-title 114
###begin article-title 115
Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression
###end article-title 115
###begin article-title 116
###xml 50 55 <span type="species:ncbi:9606">human</span>
Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation
###end article-title 116
###begin article-title 117
Vitamin D, calcium, and epidermal differentiation
###end article-title 117
###begin article-title 118
Antiproliferative role of vitamin D and its analogs-a brief overview
###end article-title 118
###begin article-title 119
The anti-proliferative effects of 1alpha, 25(OH)2 D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression
###end article-title 119
###begin article-title 120
###xml 72 77 <span type="species:ncbi:9606">human</span>
1 alpha,25-Dihydroxyvitamin D3 (calcitriol) stimulates proliferation of human circulating monocytes in vitro
###end article-title 120
###begin article-title 121
###xml 82 87 <span type="species:ncbi:9606">human</span>
Effects of vitamin D metabolites on proliferation and differentiation of cultured human epidermal keratinocytes grown in serum-free or defined culture medium
###end article-title 121
###begin article-title 122
###xml 125 130 <span type="species:ncbi:9606">human</span>
Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells
###end article-title 122
###begin article-title 123
###xml 91 96 <span type="species:ncbi:9606">human</span>
Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma
###end article-title 123
###begin article-title 124
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Induction of anchorage-independent growth of JB6 mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3
###end article-title 124
###begin article-title 125
Calcitriol enhancement of TPA-induced tumorigenic transformation is mediated through vitamin D receptor-dependent and -independent pathways
###end article-title 125
###begin article-title 126
###xml 66 71 <span type="species:ncbi:9606">human</span>
DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line
###end article-title 126
###begin article-title 127
Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer
###end article-title 127
###begin article-title 128
###xml 143 148 <span type="species:ncbi:10090">mouse</span>
1 alpha,25-Dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate- induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells
###end article-title 128
###begin article-title 129
Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling
###end article-title 129
###begin article-title 130
RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells
###end article-title 130
###begin article-title 131
###xml 83 88 <span type="species:ncbi:9606">human</span>
Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells
###end article-title 131
###begin article-title 132
RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin
###end article-title 132
###begin article-title 133
Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals
###end article-title 133
###begin article-title 134
###xml 100 103 <span type="species:ncbi:10116">rat</span>
High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells
###end article-title 134
###begin article-title 135
E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity
###end article-title 135
###begin article-title 136
The molecular basis of vitamin D receptor and beta-catenin crossregulation
###end article-title 136
###begin article-title 137
Convergence of Wnt, beta-catenin, and cadherin pathways
###end article-title 137
###begin article-title 138
Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4
###end article-title 138
###begin article-title 139
Cell adhesion: the molecular basis of tissue architecture and morphogenesis
###end article-title 139
###begin article-title 140
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies
###end article-title 140
###begin article-title 141
E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner
###end article-title 141
###begin article-title 142
Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4
###end article-title 142
###begin article-title 143
###xml 112 115 <span type="species:ncbi:10116">rat</span>
Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines
###end article-title 143
###begin article-title 144
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning
###end article-title 144
###begin article-title 145
Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction
###end article-title 145
###begin article-title 146
Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues
###end article-title 146
###begin article-title 147
The epidemiology of vitamin D and cancer incidence and mortality: a review (United States)
###end article-title 147
###begin article-title 148
Do sunlight and vitamin D reduce the likelihood of colon cancer?
###end article-title 148
###begin article-title 149
Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway)
###end article-title 149
###begin article-title 150
Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation
###end article-title 150
###begin article-title 151
Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure
###end article-title 151
###begin article-title 152
Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey
###end article-title 152
###begin article-title 153
Vitamin D and reduced risk of breast cancer: a population-based case-control study
###end article-title 153
###begin article-title 154
###xml 92 95 <span type="species:ncbi:9606">men</span>
Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men
###end article-title 154
###begin article-title 155
Selected micronutrients and colorectal cancer. A case-control study from the canton of Vaud, Switzerland
###end article-title 155
###begin article-title 156
Associations of energy, fat, calcium, and vitamin D with prostate cancer risk
###end article-title 156
###begin article-title 157
Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort
###end article-title 157
###begin article-title 158
Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales
###end article-title 158
###begin article-title 159
Ultraviolet radiation exposure and risk of non-Hodgkin's lymphoma
###end article-title 159
###begin article-title 160
Non-Hodgkin's lymphoma and sunlight
###end article-title 160
###begin article-title 161
Sun exposure may protect against non-Hodgkin lymphoma: a case-control study
###end article-title 161
###begin article-title 162
Nutrient intake and risk of non-Hodgkin's lymphoma
###end article-title 162
###begin article-title 163
Structure-function relationships in the vitamin D endocrine system
###end article-title 163
###begin article-title 164
###xml 62 67 <span type="species:ncbi:9606">women</span>
Plasma vitamin D metabolites and risk of colorectal cancer in women
###end article-title 164
###begin article-title 165
###xml 100 103 <span type="species:ncbi:9606">men</span>
Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men
###end article-title 165
###begin article-title 166
Prospective study of serum vitamin D and cancer mortality in the United States
###end article-title 166
###begin article-title 167
Plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D and risk of breast cancer
###end article-title 167
###begin article-title 168
Prediagnostic serum vitamin D and breast cancer
###end article-title 168
###begin article-title 169
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
###end article-title 169
###begin article-title 170
Vitamin D and prostate cancer: a prediagnostic study with stored sera
###end article-title 170
###begin article-title 171
Serum vitamin D concentration and prostate cancer risk: a nested case-control study
###end article-title 171
###begin article-title 172
A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers
###end article-title 172
###begin article-title 173
A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers
###end article-title 173
###begin article-title 174
Nested case-control studies
###end article-title 174
###begin article-title 175
Serum 25(OH)-vitamin D concentration and risk of esophageal squamous dysplasia
###end article-title 175
###begin article-title 176
Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers
###end article-title 176
###begin article-title 177
The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene
###end article-title 177
###begin article-title 178
Patterns of alpha- and beta-catenin and E-cadherin expression in colorectal adenomas and carcinomas
###end article-title 178
###begin article-title 179
Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer
###end article-title 179
###begin article-title 180
The yield of surveillance colonoscopy by adenoma history and time to examination
###end article-title 180
###begin article-title 181
Risk factors for oesophageal squamous dysplasia in adult inhabitants of a high risk region of China
###end article-title 181
###begin article-title 182
E-cadherin, laminin and collagen IV expression in the evolution from dysplasia to oral squamous cell carcinoma
###end article-title 182
###begin article-title 183
(OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity
###end article-title 183
###begin article-title 184
Gene expression profiling identifies markers of ampullary adenocarcinoma
###end article-title 184
###begin article-title 185
A causal role for E-cadherin in the transition from adenoma to carcinoma
###end article-title 185
###begin article-title 186
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology
###end article-title 186
###begin article-title 187
Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression
###end article-title 187
###begin article-title 188
Three-dimensional structure-function relationship of vitamin D and vitamin D receptor model
###end article-title 188
###begin article-title 189
D signalling pathways in cancer: potential for anticancer therapeutics
###end article-title 189
###begin p 190
###xml 27 28 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 30 31 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 47 48 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 50 51 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 177 178 165 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 180 181 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 465 466 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 468 469 452 453 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
Chemistry of 1alpha,25-(OH)2 D3. 1alpha,25-(OH)2 D3 is derived from the 4 cyclopentanoperhydro-phenanthrene ring structure (A, B, C, and D rings) for steroids. In 1alpha,25-(OH)2 D3, the 9,10 carbon-carbon bond of ring B is broken between ring A and rings C and D (arrow, a) and the molecule is technically classified as a seco-steroid. The molecule may then rotate along the bond between ring A and rings C and D (arrow), to provide the structure of 1alpha,25-(OH)2 D3 (a). Stepwise modification of the molecule, involving location of a oxygen atom at position 23 on the C and D ring side chain or removal of the terminal -OH group can have important biological effects (b).
###end p 190
###begin p 191
###xml 118 119 114 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 121 122 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 247 248 239 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 250 251 242 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 440 445 432 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib125" ref-type="bibr">[125]</xref>
###xml 461 464 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 498 501 490 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 575 576 563 564 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 578 579 566 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 854 855 838 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 857 858 841 842 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 455 460 <span type="species:ncbi:9606">human</span>
###xml 492 497 <span type="species:ncbi:9606">human</span>
Schematic representation of the vitamin D receptor (VDR) domain structure. (a) VDR protein backbone and 1alpha,25-(OH)2 D3 ligand-binding pocket. The VDR protein backbone is represented by a ribbon. A space-filling representation of 1alpha,25-(OH)2 D3 is shown within the VDR ligand-binding pocket by an atom-based structure. Conformational modification of the vitamin D side chain may influence ligand binding and transcriptional activity [125]. (b) The human VDR gene domain structure. The human VDR gene is composed of 9 exons that encode domains (A-F). Upon 1alpha,25(OH)2 D3 binding to the hormone ligand-binding domain, VDR is stabilized by the phosphorylation of serine 51 in the DNA-binding domain and serine 208 in the hinge region. VDR associates with the retinoic acid receptor (RXR) through the dimerization domains in E/F. The 1alpha,25-(OH)2 D3-VDR-RXR complex binds to the vitamin D response elements (VDREs) through the DNA-binding domain in the promoters of target genes. Conformational change in VDR results in co-repressor dissociation and enables interaction of the AF2 transactivation domain with stimulatory coactivators, such as steroid receptor coactivators (SRCs), vitamin D receptor-interacting proteins complex and nuclear coactivators.
###end p 191
###begin p 192
###xml 75 76 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 78 79 74 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 540 541 532 533 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 543 544 535 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1029 1036 1021 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP27B1</italic>
###xml 1070 1073 1058 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTH</italic>
###xml 1159 1160 1143 1144 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1162 1163 1146 1147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1421 1423 1405 1407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1467 1472 1451 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib126" ref-type="bibr">[126]</xref>
Transcriptional regulation by vitamin D. Classical action of 1alpha,25-(OH)2 D3 is mediated by binding of the VDR/RXR complex at VDREs. (a) Transcriptional activation involves the co-activator molecules SRCs, NCoA62, HATs, CBP p300 and other molecules to derepress chromatin. (b) Binding of DRIP to the AF2 domain attracts a complex containing transcription factor 2B (TF2B) and RNA polymerase II (RNA Pol II) for transcription initiation. The presence of the multiprotein complex facilitates increased gene transcription. (c) 1alpha,25(OH)2 D3-mediated transcriptional repression involves VDR-RXR heterodimer association with VDR-interacting repressor (VDIR) bound to E-box-type negative VDREs (nVDREs), dissociation of the HAT co-activator and recruitment of histone deacetylase (HDAC) co-repressor. Williams syndrome transcription factor (WSTF) potentiates transrepression by interacting with a multifunctional, ATP-dependent chromatin-remodelling complex (WINAC) and chromatin. This leads to the repression of genes, such as CYP27B1 (which encodes 1alpha-OHase) and PTH (which encodes parathyroid hormone). (d) Non-genomic, rapid actions of 1alpha,25-(OH)2 D3 are though activation of mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) 1 and 2 cascade through the phosphorylation (P) and activation of Raf by protein kinase C (PKC), partly through induced changes of intra-cellular Ca2+ concentration (reproduced from Deeb et al. [126] with kind permission of Dr CS Johnston Roswell Park CI, New York and the publisher).
###end p 192

